RNAC Cartesian Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Cartesian Therapeutics Inc reported revenue of $0 (down 100.0% from a year earlier), net income of $15.8M and diluted EPS of $0.46; over the last four quarters revenue was $1.48M and net income −$152M; for the fiscal year ended December 2025 revenue was $2.80M, down 92.8% on the year before.
RNAC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $2.80M, gross profit n/a, operating income −$143M, net income −$130M (margin -4658.6%), EPS −$5.02
- Fiscal year ended Dec 2024: revenue $38.9M, gross profit n/a, operating income −$43.9M, net income −$77.4M (margin -199.0%), EPS −$4.49
- Fiscal year ended Dec 2023: revenue $26.0M, gross profit n/a, operating income −$86.4M, net income −$220M (margin -844.9%), EPS −$49.76
- Fiscal year ended Dec 2022: revenue $111M, gross profit n/a, operating income $14.5M, net income $35.4M (margin 31.9%), EPS $0.10
- Fiscal year ended Dec 2021: revenue $85.1M, gross profit n/a, operating income −$4.60M, net income −$25.7M (margin -30.2%), EPS −$0.22
RNAC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income $15.8M, EPS $0.46
- Quarter ended Mar 31, 2026: revenue $78.0K (down 92.9% year over year), net income −$39.2M, EPS −$1.46
- Quarter ended Dec 31, 2025 (from the annual report): revenue $947K (up 224.8% year over year), net income −$92.6M, EPS −$3.46
- Quarter ended Sep 30, 2025: revenue $452K (up 16.8% year over year), net income −$35.9M, EPS −$1.38
- Quarter ended Jun 30, 2025: revenue $298K (down 99.1% year over year), net income $15.9M, EPS $0.50
- Quarter ended Mar 31, 2025: revenue $1.10M (down 81.2% year over year), net income −$17.7M, EPS −$0.68
- Quarter ended Dec 31, 2024 (from the annual report): revenue −$759K (down 109.2% year over year), net income −$10.3M, EPS $6.60
- Quarter ended Sep 30, 2024: revenue $387K (down 94.1% year over year), net income −$24.2M, EPS −$1.13
- Quarter ended Jun 30, 2024: revenue $33.4M (up 537.2% year over year), net income $13.8M, EPS $0.54
- Quarter ended Mar 31, 2024: revenue $5.84M (down 1.7% year over year), net income −$56.8M, EPS −$10.50
- Quarter ended Dec 31, 2023 (from the annual report): revenue $8.27M (down 50.8% year over year), net income −$178M, EPS −$41.55
- Quarter ended Sep 30, 2023: revenue $6.55M (down 68.4% year over year), net income −$9.00M, EPS −$1.74
- Quarter ended Jun 30, 2023: revenue $5.25M (down 86.6% year over year), net income −$11.4M, EPS −$2.23
- Quarter ended Mar 31, 2023: revenue $5.94M (down 82.5% year over year), net income −$21.7M, EPS −$4.24
- Quarter ended Dec 31, 2022 (from the annual report): revenue $16.8M (down 43.9% year over year), net income $5.89M, EPS $0.01
- Quarter ended Sep 30, 2022: revenue $20.7M (down 15.2% year over year), net income −$7.89M, EPS −$0.05
- Quarter ended Jun 30, 2022: revenue $39.3M (up 99.7% year over year), net income $8.60M, EPS $0.06
- Quarter ended Mar 31, 2022: revenue $34.0M (up 207.7% year over year), net income $28.8M, EPS $0.08
- Quarter ended Dec 31, 2021 (from the annual report): revenue $29.9M, net income $12.2M, EPS $0.16
- Quarter ended Sep 30, 2021: revenue $24.4M, net income −$17.9M, EPS −$0.16
RNAC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$73.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$23.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$51.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$31.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$60.4M, share buybacks n/a
RNAC balance sheet
- Jun 30, 2026: cash $148M, total assets $319M, total liabilities $444M, shareholders' equity −$125M, long-term debt $52.9M
- Mar 31, 2026: cash $119M, total assets $288M, total liabilities $437M, shareholders' equity −$148M
- Dec 31, 2025: cash $125M, total assets $296M, total liabilities $423M, shareholders' equity −$126M, long-term debt $0
- Sep 30, 2025: cash $143M, total assets $373M, total liabilities $409M, shareholders' equity −$35.8M
- Jun 30, 2025: cash $160M, total assets $389M, total liabilities $391M, shareholders' equity −$2.53M
- Mar 31, 2025: cash $180M, total assets $409M, total liabilities $431M, shareholders' equity −$21.8M
- Dec 31, 2024: cash $213M, total assets $435M, total liabilities $442M, shareholders' equity −$6.80M
- Sep 30, 2024: cash $219M, total assets $455M, total liabilities $455M, shareholders' equity $752K
What is RNAC's revenue?
Cartesian Therapeutics Inc reported $1.48M of revenue over its last four quarters, through June 30, 2026.
Is RNAC profitable?
No. Cartesian Therapeutics Inc lost $152M over the last four quarters.
What is RNAC's EPS?
Diluted earnings per share over the last four quarters were −$5.84; $0.46 in the latest quarter.